Openbookopenbook
Equity
TSTL
+0.0 · +0.00%
GBX · LSE

Tristel(TSTL) Stock Analysis | Healthcare

GBX --+0.00%
Reward76High
Risk13Low
75%Data
Strong 16% profit margin · 3.4% dividend yield · Revenue growing 14% YoY
Quality Compounder
Market Cap:200.71M
ⓘ
Reward Rating
76
High
Reward Assessment
75% data coverage
Top 10% of stocksView factors
ⓘ
Risk Rating
13
Low
Risk Assessment
2 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on TSTL to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for TSTL, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 475p.

What is Tristel?

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally.

TSTL · Verdict

Strong reward · low risk

TSTL scores well on profitability and volatility with no major weaknesses flagged in the model.

Based on 88% data coverage

TSTL · Verdict

What’s working & what to watch

Strengths 6

  • Profitability97/100

    14% net margin · 24% ROE

  • Volatility95/100

    Top decile vs peers

  • Balance sheet92/100

    Interest covered 33.5×

  • Cash flow91/100

    20% free-cash-flow margin

  • Growth84/100

    Rev +14.3% CAGR · earnings +88.8%

  • Valuation67/100

    P/E 21.6× · PEG 1.30

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Tristel?

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom, Australia, Germany, Western Europe, and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 200.71M, and a P/E ratio of 26.1x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (76)

The scoring profile indicates a strong reward potential, driven primarily by profitability and growth. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Medical Instruments & Supplies names that are close enough in size to make side-by-side comparison useful.

SPECMicro Cap / 106M market cap
Inspecs Group plc
Compare
AMSSmall Cap / 611M market cap
Advanced Medical Solutions Group plc
Compare
BVCNano Cap / 42.2M market cap
Batm Advanced Communications Ltd
Compare
Company Information
SectorHealthcare
IndustryMedical Instruments & Supplies
Market Cap200.71M
P/E Ratio26.0938
Dividend Yield3.40%
Beta0.346
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.